Results 111 to 120 of about 215,700 (362)

Thought-stopping on insomnia.

, 1982
The purpose of this study was twofold: (a) to examine the effects of thought-stopping on chronic primary initial insomniacs, and (b) to test the attribution model of insomnia.
Villiotis, Stamatios G.
core  

Suvorexant for insomnia in older adults: a perspective review

, 2018
The aim of this review was to identify published randomized control trials (RCTs) that evaluated the efficacy and tolerability of suvorexant for the treatment of insomnia among older adults (≥65 years).
Silpa Balachandran, Stephanie Hrisko, Piyush Taparia, Geetha Manikkara, Rajesh R Tampi, Deena J Tampi, Shilpa Srinivasan   +6 more
core   +1 more source

The small molecule simufilam dose‐dependently attenuates the worsening of seizures in a mouse model of tuberous sclerosis complex

Epilepsia, EarlyView.
Abstract Objective Novel epilepsy treatments for patients with tuberous sclerosis complex (TSC) and focal cortical dysplasia type II (FCDII) are urgently needed. In these patients, mutations in the mechanistic target of rapamycin (mTOR) pathway genes lead to mTOR hyperactivity and focal cortical malformations that frequently cause intractable epilepsy ...
Branden Stansley, Md. Monirul Islam, Dean J. Aguiar, Zoë Fuchs, Mackenzie Catron, Stephen Morairty, Ying Yuan, Radleigh Santos, Jingguo Hou, Annelies de Kater, George B. Thornton, Angelique Bordey   +11 more
wiley   +1 more source

Insomnia: a cultural history [PDF]

, 2018
Kimberley Whitehead, Matthew Beaumont
openalex   +1 more source

Are comorbid sleep disorders associated with higher risk for sudden unexpected death in epilepsy? Observations from a Canadian epilepsy clinic

Epilepsia, EarlyView.
Abstract Objective Pooled mortality is nearly three times higher in people with epilepsy (PWE). Approximately 80% of sudden unexpected death in epilepsy (SUDEP) events occur during sleep, and primary sleep disorders are prevalent in the general population and PWE.
Marion Lazaj, Ellen Lee, Tristan Derry, Helen Driver, Gavin P. Winston, Lysa Boissé Lomax, Ana Johnson, Garima Shukla   +7 more
wiley   +1 more source

Deterioration of sleep and mental health in individuals with insomnia during South Africa’s COVID-19 lockdown

South African Journal of Science
Sleep and mental health difficulties have been observed in response to COVID-19 pandemic-induced lockdowns, but few studies have described the impact of lockdown on individuals with self-reported insomnia.
Alison Bentley, Laura C. Roden, Jonathan P. Davy, Stella Iacovides, F. Xavier Gómez-Olivé, Karine Scheuermaier, Raphaella Lewis, Gosia Lipinska, Johanna Roche, Candice J. Christie, Swantje Wells, Dale E. Rae   +11 more
doaj   +1 more source

Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon

, 2013
This review explores basic sleep physiology, the mechanism of action for each class of hypnotic agents, their clinical application based on pharmacodynamic and pharmacokinetic factors, and potential pharmacologic sleep-inducing mechanisms of future ...
Thomas L Schwartz, Viral Goradia
core   +1 more source

Fatal Familial Insomnia with Early Dysautonomia and Diabetes [PDF]

, 2020
Ran R. Liu, Michel Melanson, Nathaniel Bendahan, Deborah E. Briggs, Sean Taylor, Lysa Boissé Lomax   +5 more
openalex   +1 more source

Unveiling sleep disturbances in KCNB1‐related disorders: Insights from a cohort of 78 individuals

Epilepsia Open, EarlyView.
Abstract Objectives Sleep disturbances are frequent comorbidities in epilepsies and developmental encephalopathies. This study aimed to characterize sleep abnormalities in individuals with KCNB1‐related disorders, focusing on their prevalence, clinical manifestations, and impact on daily functioning.
Giovanna Scorrano, Delphine Breuillard, Anais Thimon, Nicole Chemaly, Rima Nabbout   +4 more
wiley   +1 more source

Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non‐Small Cell Lung Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background LIBRETTO‐001 is an ongoing, global, open‐label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient‐reported outcomes in patients with RET fusion–positive non‐small cell lung cancer (NSCLC).
Anna Minchom, Aaron C. Tan, Erminia Massarelli, Vivek Subbiah, Valentina Boni, Bruce Robinson, Lori J. Wirth, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Caroline E. McCoach   +11 more
wiley   +1 more source